RATIONALE: Pregnancy is an immunological condition with a series of changes. To explore whether DNA-Methylation (DNA-M) is related to these changes in consecutive gestations, we analyzed the DNA-M of T H 1, T H 2, T H 17 and T reg pathway genes in two consecutive pregnancies of multiparous women. METHODS: Blood samples were collected in first (weeks 8-21) and second (weeks 22-38) halves of pregnancy from the Isle of Wight birth cohort to measure DNA-M using Illumina Infinium Human Methylation450 beadchip. DNA-M was obtained in first (13 mothers) and second (8 mothers) halves for two consecutive pregnancies. First, mixed linear models were used to compare DNA-M across two consecutive pregnancies, separately for first and second halves, to detect cytosinephosphate-guanine (CpG) sites with significant changes (p< _0.05) in T H 1 (155 CpGs, 19 genes), T H 2 (77 CpGs, 12 genes), T H 17 (106 CpGs, 15 genes) and T reg (10 CpGs, 2 genes). Then we compared the proportion of significant CpGs to determine whether T cell pathway CpGs were more often different than 20 random samples each containing 348 CpGs. RESULTS: Only Th17 CpGs in the second half of pregnancy were differentially methylated in two consecutive pregnancies. Among the 28 significantly differentially methylated Th17 CpGs, 24 belong to IL17-family and four to IL21-family. Compared to changes in random samples (14.1-17.8%), the methylation of more CpGs in T H 17 (26.4%) were significantly more often changed in the second half of pregnancy. CONCLUSIONS: Significant more methylation changes in T H 17 genes in the second half of gestation comparing consecutive pregnancies may suggest changes in methylation with parity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.